Method of treating inflammation

1. A method of treating systemic, regional, or local inflammation from a patient suffering inflammation, said method comprising administration of a therapeutically effective dose of a sorbent for an inflammatory mediator in said patient; wherein the sorbent is a biocompatible polymer that comprises a cross-linked, porous styrene or divinylbenzene copolymer; the biocompatible polymer having a pore structure that the total pore volume of pore size in the range of 50 {acute over (Å)} to 3000 {acute over (Å)} is greater than 0.5 cc/g to 3.0 cc/g dry polymer;

wherein said inflammatory mediator comprises cytokines.

2. The method of claim 1 , wherein said inflammatory mediator is present in physiological fluid or a carrier fluid in the patient.

3. The method of claim 2 , wherein said physiological fluids is nasopharyngeal, oral, esophageal, gastric, pancreatic, hepatic, pleural, pericardial, peritoneal, intestinal, prostatic, seminal, vaginal secretions, tears, saliva, mucus, bile, blood, lymph, plasma, serum, synovial fluid, cerebrospinal fluid, urine, and interstitial, intracellular, or extracellular fluid.

4. The method of claim 1 , wherein said dose of sorbent is administered orally, via a feeding tube, peritoneally, or rectally.

5. The method of claim 1 , wherein said inflammatory mediator is associated with systemic inflammatory response syndrome (SIRS) or sepsis, autoimmune disease, surgery, cytotoxic chemotherapy, bone marrow manipulation, major tissue injury or trauma, mesenteric hypoperfusion, gut-mucosal injury, malaria, gastrointestinal inflammatory disease, enteric infection, influenza, acute lung inflammation, pulmonary embolism, pancreatitis, autoimmune and collagen vascular diseases, transfusion-related diseases, burn injury, smoke or inhalation lung injury, graft versus host disease, ischemia or infarction, hemorrhage, anaphylaxis, drug overdose, reperfusion injury, radiation injury or chemical injury.

6. The method of claim 1 , wherein said inflammatory mediator results from a disease caused by biowarfare pathogens, toxins or agents.

7. The method of claim 1 , wherein said sorbent is a biocompatible polymer.

8. The method of claim 7 , wherein said biocompatible polymer is supplied as a slurry, or suspension, or dry powder or other dry particulate capable of being wetted.

9. The method of claim 7 , wherein said sorbent is supplied as a slurry or suspension packaged in either single dose or multidose packages for oral administration.

10. The method of claim 7 , wherein said sorbent is supplied as a slurry or suspension packaged in either single dose or multidose packages for administration by enema or feeding tube or any combination therein.

11. The method of claim 7 , wherein said biocompatible polymer is supplied as a dry powder or other dry particulate capable of being wetted externally or internally in the alimentary canal, including in the gastric or enteric environment, with or without the addition of wetting agents like ethyl alcohol.

12. The method of claim 10 , wherein said biocompatible polymer is supplied as tablet, dry powder, other dry particulate, capsule or suppository packaged in bottles or blister packs for administration.

13. The method of claim 8 , wherein said biocompatible polymer materials is not metabolizable by human and animal.

14. The method of claim 8 , wherein said biocompatible polymer comprises particles having a diameter in the range for 0.1 micron meters to 2 centimeters.

15. The method of claim 14 , wherein said biocompatible polymer is in the form of powder, beads or other regular or irregularly shaped particulate.

16. The method of claim 7 , wherein:

said biocompatible polymer has a pore structure that the total pore volume of pore size in the range of 50 {acute over (Å)} to 3000 {acute over (Å)} is greater than 0.5 cc/g to 3.0 cc/g dry polymer;

wherein the Ratio of Pore Volume between 50 {acute over (Å)} to 3,000 {acute over (Å)} in diameter To Pore Volume between 500 {acute over (Å)} to 3,000 {acute over (Å)} in diameter of the said biocompatible polymer is smaller than 200:1; and

wherein the Ratio of Pore Volume between 50 {acute over (Å)} to 3,000 {acute over (Å)} in diameter To Pore Volume between 1,000 {acute over (Å)} to 3,000 {acute over (Å)} in diameter of said biocompatible polymer is greater than 20:1.

17. The method of claim 7 , wherein said biocompatible polymer is a coated polymer comprising at least one crosslinking agent and at least one dispersing agent;

said dispersing agents such as hydroxyethyl cellulose, hydroxypopyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylamimoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), and salts of poly(acrylic acid) and mixtures thereof;

said crosslinking agent selected from a group consisting of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triiacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, divinylformamide and mixtures thereof;

said polymer being developed simultaneously with the formation of the coating, wherein said dispersing agent is chemically bound to said surface of said biocompatible polymer.

18. The method of claim 7 , wherein said biocompatible polymer is an ion exchange polymer.

19. The method of claim 7 , wherein said biocompatible polymer is modified with an antibody or ligand and may be porous or solid.

20. The method of claim 1 , wherein said biocompatible polymer is a porous highly crosslinked styrene or divinylbenzene copolymer.

21. The method of claim 20 , wherein said porous highly crosslinked styrene or divinylbenzene copolymer is a macroporous or mesoporous styrene-divinylbenzene-ethylstyrene copolymer subjected to a partial chloromethylation to a chlorine content of up to 7% molecular weight.

22. The method of claim 20 , wherein said porous highly crosslinked styrene or divinylbenzene copolymer is a hypercrosslinked polystyrene produced from crosslinked styrene copolymers by an extensive chloromethylation and a subsequent post-crosslinking by treating with a Friedel-Crafts catalyst in a swollen state.

23. The method of claim 20 , wherein said porous highly crosslinked styrene or divinylbenzene copolymer is a hypercrosslinked polystyrene produced from crosslinked styrene copolymers by an extensive additional post-crosslinking in a swollen state with bifunctional crosslinking agents selected from the group comprising of monochlorodimethyl ether and p-xylilene dichloride.

24. The method of claim 7 , wherein said biocompatible polymer is a hydrophilic self wetting polymer that can be administered as dry powder or dry particulate containing hydrophilic functional groups such as chlorine, amines, hydroxyl, sulfonate, and carboxyl groups.